{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:32:39Z","timestamp":1790893959203,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"48","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,12,15]]},"DOI":"10.1038\/s41388-025-03625-4","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T19:24:27Z","timestamp":1763148267000},"page":"4747-4762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Hepatitis B virus X protein promotes the progression and immune escape of hepatocellular carcinoma by activating KLF16-C12orf49-PD-L1 axis"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1028-6319","authenticated-orcid":false,"given":"Wenbiao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiuxiu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-4669","authenticated-orcid":false,"given":"Jun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"3625_CR1","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1002\/med.22030","volume":"44","author":"RAA Ponde","year":"2024","unstructured":"Ponde RAA, Amorim GSP. Elimination of the hepatitis B virus: a goal, a challenge. Med Res Rev. 2024;44:2015\u201334.","journal-title":"Med Res Rev"},{"key":"3625_CR2","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/v14050986","volume":"14","author":"GEM Rizzo","year":"2022","unstructured":"Rizzo GEM, Cabibbo G, Craxi A. Hepatitis B virus-associated hepatocellular carcinoma. Viruses. 2022;14:986.","journal-title":"Viruses"},{"key":"3625_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3350\/cmh.2022.0342","volume":"29","author":"CL Lin","year":"2023","unstructured":"Lin CL, Kao JH. Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection. Clin Mol Hepatol. 2023;29:605\u201322.","journal-title":"Clin Mol Hepatol"},{"key":"3625_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2147\/JHC.S307962","volume":"8","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Han Q, Zhao H, Zhang J. The Mechanisms of HBV-Induced Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021;8:435\u201350.","journal-title":"J Hepatocell Carcinoma"},{"key":"3625_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3390\/cancers15020533","volume":"15","author":"C Shen","year":"2023","unstructured":"Shen C, Jiang X, Li M, Luo Y. Hepatitis virus and hepatocellular carcinoma: recent advances. Cancers. 2023;15:533.","journal-title":"Cancers"},{"key":"3625_CR6","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2147\/IJGM.S462844","volume":"17","author":"H Wang","year":"2024","unstructured":"Wang H, Hu B, Liang H, Wang R, Wei L, Su T, et al. Impact of HBV integration on hepatocellular carcinoma after long-term antiviral therapy. Int J Gen Med. 2024;17:2643\u201353.","journal-title":"Int J Gen Med"},{"key":"3625_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2024.2421231","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Cao W, Wang S, Zhang L, Li X, Zhang Z, et al. Epigenetic modification of hepatitis B virus infection and related hepatocellular carcinoma. Virulence. 2024;15:2421231.","journal-title":"Virulence"},{"key":"3625_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1407434","volume":"14","author":"W Yan","year":"2024","unstructured":"Yan W, Rao D, Fan F, Liang H, Zhang Z, Dong H. Hepatitis B virus X protein and TGF-beta: partners in the carcinogenic journey of hepatocellular carcinoma. Front Oncol. 2024;14:1407434.","journal-title":"Front Oncol"},{"key":"3625_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1497427","volume":"14","author":"J Xu","year":"2024","unstructured":"Xu J, Cheng W, Wang Y, Zhou Y, Wang Z, Dai Y, et al. KIF20A activated by transcription factor GATA2 promotes cell growth in hepatitis B virus-related hepatocellular carcinoma. Front Cell Infect Microbiol. 2024;14:1497427.","journal-title":"Front Cell Infect Microbiol"},{"key":"3625_CR10","doi-asserted-by":"publisher","first-page":"4942","DOI":"10.7150\/ijbs.112133","volume":"21","author":"ZB Du","year":"2025","unstructured":"Du ZB, Wu XM, Han T, Cai YX, Qian B, Shen YS, et al. MALAT1 promotes malignancy of HBV-related hepatocellular carcinoma by regulating IGF2BP3-mediated nuclear-cytoplasmic shuttling. Int J Biol Sci. 2025;21:4942\u201360.","journal-title":"Int J Biol Sci"},{"key":"3625_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01500-4","volume":"21","author":"Y An","year":"2022","unstructured":"An Y, Duan H. The role of m6A RNA methylation in cancer metabolism. Mol Cancer. 2022;21:14.","journal-title":"Mol Cancer"},{"key":"3625_CR12","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1080\/22221751.2021.2006580","volume":"10","author":"A Kostyusheva","year":"2021","unstructured":"Kostyusheva A, Brezgin S, Glebe D, Kostyushev D, Chulanov V. Host-cell interactions in HBV infection and pathogenesis: the emerging role of m6A modification. Emerg Microbes Infect. 2021;10:2264\u201375.","journal-title":"Emerg Microbes Infect"},{"key":"3625_CR13","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1111\/jgh.15999","volume":"37","author":"C Zhang","year":"2022","unstructured":"Zhang C, Dai D, Zhang W, Yang W, Guo Y, Wei Q. Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma. J Gastroenterol Hepatol. 2022;37:2039\u201350.","journal-title":"J Gastroenterol Hepatol"},{"key":"3625_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2025.118254","volume":"298","author":"X Zhou","year":"2025","unstructured":"Zhou X, Li T, Xie H, Huang H, Yang K, Zeng X, et al. HBV-induced N6 methyladenosine modification of PARP1 enhanced AFB1-related DNA damage and synergistically contribute to HCC. Ecotoxicol Environ Saf. 2025;298:118254.","journal-title":"Ecotoxicol Environ Saf"},{"key":"3625_CR15","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1158\/1541-7786.MCR-23-0720","volume":"22","author":"Y Meng","year":"2024","unstructured":"Meng Y, Shu Z, Wang X, Hong L, Wang B, Jiang J, et al. Hepatitis B virus-mediated m6A demethylation increases hepatocellular carcinoma stemness and immune escape. Mol Cancer Res. 2024;22:642\u201355.","journal-title":"Mol Cancer Res"},{"key":"3625_CR16","doi-asserted-by":"publisher","first-page":"e2019455118","DOI":"10.1073\/pnas.2019455118","volume":"118","author":"GW Kim","year":"2021","unstructured":"Kim GW, Siddiqui A. Hepatitis B virus X protein recruits methyltransferases to affect cotranscriptional N6-methyladenosine modification of viral\/host RNAs. Proc Natl Acad Sci USA. 2021;118:e2019455118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3625_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1606277","volume":"16","author":"JM Salmon","year":"2025","unstructured":"Salmon JM, Adams H, Magor GW, Perkins AC. KLF feedback loops in innate immunity. Front Immunol. 2025;16:1606277.","journal-title":"Front Immunol"},{"key":"3625_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.723","volume":"5","author":"T Xiang","year":"2024","unstructured":"Xiang T, Yang C, Deng Z, Sun D, Luo F, Chen Y. Kruppel-like factors family in health and disease. MedComm. 2024;5:e723.","journal-title":"MedComm"},{"key":"3625_CR19","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.2147\/CMAR.S256490","volume":"12","author":"S Bang","year":"2020","unstructured":"Bang S, Li J, Zhang M, Cui R, Wu X, Xin Z, et al. The clinical relevance and function of Kruppel-like factor 16 in breast cancer. Cancer Manag Res. 2020;12:6373\u201383.","journal-title":"Cancer Manag Res"},{"key":"3625_CR20","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1016\/j.ymthe.2022.04.022","volume":"30","author":"XD Ma","year":"2022","unstructured":"Ma XD, Xu SD, Hao SH, Han K, Chen JW, Ling H, et al. KLF16 enhances stress tolerance of colorectal carcinomas by modulating nucleolar homeostasis and translational reprogramming. Mol Ther. 2022;30:2828\u201343.","journal-title":"Mol Ther"},{"key":"3625_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05534-w","volume":"14","author":"Z Yang","year":"2023","unstructured":"Yang Z, Wang YX, Wen JK, Gao HT, Han ZW, Qi JC, et al. SF3B4 promotes Twist1 expression and clear cell renal cell carcinoma progression by facilitating the export of KLF 16 mRNA from the nucleus to the cytoplasm. Cell Death Dis. 2023;14:26.","journal-title":"Cell Death Dis"},{"key":"3625_CR22","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.4251\/wjgo.v14.i11.2157","volume":"14","author":"W Mi","year":"2022","unstructured":"Mi W, Zheng Z, Lu JD, Duan SQ, Zhang J, Zhang HQ, et al. KLF16 promotes pancreatic adenocarcinoma cell proliferation and migration by positively regulating SMAD6. World J Gastrointest Oncol. 2022;14:2157\u201369.","journal-title":"World J Gastrointest Oncol"},{"key":"3625_CR23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1080\/21691401.2018.1431654","volume":"46","author":"X Chen","year":"2018","unstructured":"Chen X, Li S, Ke Y, Wu S, Huang T, Hu W, et al. KLF16 suppresses human glioma cell proliferation and tumourigenicity by targeting TFAM. Artif Cells Nanomed Biotechnol. 2018;46:608\u201315.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"3625_CR24","doi-asserted-by":"publisher","first-page":"9081","DOI":"10.1002\/jcb.27167","volume":"119","author":"L Zhang","year":"2018","unstructured":"Zhang L, Cao Y, Wei M, Jiang X, Jia D. Long noncoding RNA-RNCR3 overexpression deleteriously affects the growth of glioblastoma cells through miR-185-5p\/Kruppel-like factor 16 axis. J Cell Biochem. 2018;119:9081\u20139.","journal-title":"J Cell Biochem"},{"key":"3625_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s42255-020-0206-9","volume":"2","author":"EC Bayraktar","year":"2020","unstructured":"Bayraktar EC, La K, Karpman K, Unlu G, Ozerdem C, Ritter DJ, et al. Metabolic coessentiality mapping identifies C12orf49 as a regulator of SREBP processing and cholesterol metabolism. Nat Metab. 2020;2:487\u201398.","journal-title":"Nat Metab"},{"key":"3625_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14811-1","volume":"11","author":"A Loregger","year":"2020","unstructured":"Loregger A, Raaben M, Nieuwenhuis J, Tan JME, Jae LT, van den Hengel LG, et al. Haploid genetic screens identify SPRING\/C12ORF49 as a determinant of SREBP signaling and cholesterol metabolism. Nat Commun. 2020;11:1128.","journal-title":"Nat Commun"},{"key":"3625_CR27","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1007\/s10620-022-07751-x","volume":"68","author":"Y Tao","year":"2023","unstructured":"Tao Y, Luo J, Zhu H, Chu Y, Pei L. Chromosome 12 open reading frame 49 promotes tumor growth and predicts poor prognosis in colorectal cancer. Dig Dis Sci. 2023;68:1306\u201315.","journal-title":"Dig Dis Sci"},{"key":"3625_CR28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41420-025-02480-2","volume":"11","author":"HC Yu","year":"2025","unstructured":"Yu HC, Jin L, Bai L, Zhang YJ, Yang ZX. C12ORF49 inhibits ferroptosis in hepatocellular carcinoma cells via reprogramming SREBP1\/SCD1-mediated lipid metabolism. Cell Death Discov. 2025;11:178.","journal-title":"Cell Death Discov"},{"key":"3625_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112882","volume":"149","author":"XM Li","year":"2022","unstructured":"Li XM, Wu HL, Xia QD, Zhou P, Wang SG, Yu X, et al. Novel insights into the SPOP E3 ubiquitin ligase: From the regulation of molecular mechanisms to tumorigenesis. Biomed Pharmacother. 2022;149:112882.","journal-title":"Biomed Pharmacother"},{"key":"3625_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/0008-5472.CAN-22-2801","volume":"83","author":"H Zhang","year":"2023","unstructured":"Zhang H, Jin X, Huang H. Deregulation of SPOP in cancer. Cancer Res. 2023;83:489\u201399.","journal-title":"Cancer Res"},{"key":"3625_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bbrc.2018.05.115","volume":"502","author":"P Ji","year":"2018","unstructured":"Ji P, Liang S, Li P, Xie C, Li J, Zhang K, et al. Speckle-type POZ protein suppresses hepatocellular carcinoma cell migration and invasion via ubiquitin-dependent proteolysis of SUMO1\/sentrin specific peptidase 7. Biochem Biophys Res Commun. 2018;502:30\u201342.","journal-title":"Biochem Biophys Res Commun"},{"key":"3625_CR32","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/cas.70025","volume":"116","author":"W Chang","year":"2025","unstructured":"Chang W, Feng K, Zhou P, Gong D, Wang K, Huang A, et al. SPOP suppresses hepatocellular carcinoma growth and metastasis by ubiquitination and proteasomal degradation of TRAF6. Cancer Sci. 2025;116:1295\u2013307.","journal-title":"Cancer Sci"},{"key":"3625_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202306827","volume":"11","author":"K Li","year":"2024","unstructured":"Li K, Zhang J, Lyu H, Yang J, Wei W, Wang Y, et al. CSN6-SPOP-HMGCS1 axis promotes hepatocellular carcinoma progression via YAP1 activation. Adv Sci. 2024;11:e2306827.","journal-title":"Adv Sci"},{"key":"3625_CR34","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41388-022-02589-z","volume":"42","author":"P Zhou","year":"2023","unstructured":"Zhou P, Chang WY, Gong DA, Huang LY, Liu R, Liu Y, et al. O-GlcNAcylation of SPOP promotes carcinogenesis in hepatocellular carcinoma. Oncogene. 2023;42:725\u201336.","journal-title":"Oncogene"},{"key":"3625_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00018-024-05144-z","volume":"81","author":"Z Yu","year":"2024","unstructured":"Yu Z, Wu X, Zhu J, Yan H, Li Y, Zhang H, et al. BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma. Cell Mol Life Sci. 2024;81:82.","journal-title":"Cell Mol Life Sci"},{"key":"3625_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3724\/abbs.2024152","volume":"57","author":"T Deng","year":"2024","unstructured":"Deng T, Ma J. Structures and mechanisms of the RNA m (6)A writer. Acta Biochim Biophys Sin (Shanghai). 2024;57:59\u201372.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"3625_CR37","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1042\/BST20230574","volume":"52","author":"G Wei","year":"2024","unstructured":"Wei G. RNA m6A modification, signals for degradation or stabilisation?. Biochem Soc Trans. 2024;52:707\u201317.","journal-title":"Biochem Soc Trans"},{"key":"3625_CR38","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/s42003-025-08443-8","volume":"8","author":"Z Liu","year":"2025","unstructured":"Liu Z, Naz W, Yousaf T, Sun J, Wu Q, Guo M, et al. Viral-Track integrated single-cell RNA-sequencing reveals HBV lymphotropism and immunosuppressive microenvironment in HBV-associated hepatocellular carcinoma. Commun Biol. 2025;8:1030.","journal-title":"Commun Biol"},{"key":"3625_CR39","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/1744666X.2023.2198209","volume":"19","author":"E Allahmoradi","year":"2023","unstructured":"Allahmoradi E, Mohammadi R, Kheirandish Zarandi P, Alavian SM, Heiat M. The CD8+ T cell exhaustion mechanisms in chronic hepatitis B infection and immunotherapeutic strategies: a systematic review. Expert Rev Clin Immunol. 2023;19:671\u201388.","journal-title":"Expert Rev Clin Immunol"},{"key":"3625_CR40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41420-025-02540-7","volume":"11","author":"Y Li","year":"2025","unstructured":"Li Y, Zhu J, Zhai F, Ge Y, Zhan Z, Wang S, et al. LMNB2-mediated high PD-L1 transcription triggers the immune escape of hepatocellular carcinoma. Cell Death Discov. 2025;11:269.","journal-title":"Cell Death Discov"},{"key":"3625_CR41","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.str.2025.05.005","volume":"33","author":"G Xie","year":"2025","unstructured":"Xie G, Gao L, Lu R, Tian L, Zheng T, Li X, et al. Biochemical analysis of PD-L1 ubiquitination by CRL3(SPOP), ARIH1, and NEDD4 family ubiquitin ligases. Structure. 2025;33:1304\u201313.e4.","journal-title":"Structure"},{"key":"3625_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1323581","volume":"14","author":"L Hao","year":"2023","unstructured":"Hao L, Li S, Deng J, Li N, Yu F, Jiang Z, et al. The current status and future of PD-L1 in liver cancer. Front Immunol. 2023;14:1323581.","journal-title":"Front Immunol"},{"key":"3625_CR43","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"3625_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1249198","volume":"13","author":"Z Wang","year":"2023","unstructured":"Wang Z, Li N, Cai P, Zhang C, Cao G, Yin J. Mechanism of HBx carcinogenesis interaction with non-coding RNA in hepatocellular carcinoma. Front Oncol. 2023;13:1249198.","journal-title":"Front Oncol"},{"key":"3625_CR45","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s12072-022-10351-6","volume":"16","author":"L Yang","year":"2022","unstructured":"Yang L, Zou T, Chen Y, Zhao Y, Wu X, Li M, et al. Hepatitis B virus X protein mediated epigenetic alterations in the pathogenesis of hepatocellular carcinoma. Hepatol Int. 2022;16:741\u201354.","journal-title":"Hepatol Int"},{"key":"3625_CR46","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/iub.2438","volume":"73","author":"X Rao","year":"2021","unstructured":"Rao X, Lai L, Li X, Wang L, Li A, Yang Q. N(6) -methyladenosine modification of circular RNA circ-ARL3 facilitates Hepatitis B virus-associated hepatocellular carcinoma via sponging miR-1305. IUBMB Life. 2021;73:408\u201317.","journal-title":"IUBMB Life"},{"key":"3625_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08449-5","volume":"21","author":"S Qu","year":"2021","unstructured":"Qu S, Jin L, Huang H, Lin J, Gao W, Zeng Z. A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis. BMC Cancer. 2021;21:686.","journal-title":"BMC Cancer"},{"key":"3625_CR48","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1038\/s12276-023-01108-8","volume":"55","author":"J Yu","year":"2023","unstructured":"Yu J, Li W, Hou GJ, Sun DP, Yang Y, Yuan SX, et al. Circular RNA cFAM210A, degradable by HBx, inhibits HCC tumorigenesis by suppressing YBX1 transactivation. Exp Mol Med. 2023;55:2390\u2013401.","journal-title":"Exp Mol Med"},{"key":"3625_CR49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41392-023-01316-8","volume":"8","author":"Y Yang","year":"2023","unstructured":"Yang Y, Yan Y, Yin J, Tang N, Wang K, Huang L, et al. O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N(6)-methyladenosine-dependent manner. Signal Transduct Target Ther. 2023;8:63.","journal-title":"Signal Transduct Target Ther"},{"key":"3625_CR50","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/hep.31313","volume":"73","author":"GW Kim","year":"2021","unstructured":"Kim GW, Imam H, Khan M, Mir SA, Kim SJ, Yoon SK, et al. HBV-induced increased N6 methyladenosine modification of PTEN RNA affects innate immunity and contributes to HCC. Hepatology. 2021;73:533\u201347.","journal-title":"Hepatology"},{"key":"3625_CR51","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2147\/ITT.S528709","volume":"14","author":"M Akabane","year":"2025","unstructured":"Akabane M, Chatzipanagiotou OP, Imaoka Y, Schenk A, Pawlik TM. Advancing adjuvant immunotherapy in hepatocellular carcinoma: a comprehensive review. Immunotargets Ther. 2025;14:631\u201354.","journal-title":"Immunotargets Ther"},{"key":"3625_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05069-y","volume":"22","author":"Y Jia","year":"2024","unstructured":"Jia Y, Zhao J, Wang C, Meng J, Zhao L, Yang H, et al. HBV DNA polymerase upregulates the transcription of PD-L1 and suppresses T cell activity in hepatocellular carcinoma. J Transl Med. 2024;22:272.","journal-title":"J Transl Med"},{"key":"3625_CR53","doi-asserted-by":"publisher","first-page":"e001377","DOI":"10.1136\/jitc-2020-001377","volume":"8","author":"Z Chen","year":"2020","unstructured":"Chen Z, Chen Y, Peng L, Wang X, Tang N. 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1. J Immunother Cancer. 2020;8:e001377.","journal-title":"J Immunother Cancer"},{"key":"3625_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1107483","volume":"14","author":"L Gao","year":"2023","unstructured":"Gao L, Hong Z, Lei G, Guo AL, Wang FS, Jiao YM, et al. Decreased granzyme-B expression in CD11c(+)CD8(+) T cells associated with disease progression in patients with HBV-related hepatocellular carcinoma. Front Immunol. 2023;14:1107483.","journal-title":"Front Immunol"},{"key":"3625_CR55","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/HEP.0000000000000369","volume":"78","author":"M You","year":"2023","unstructured":"You M, Gao Y, Fu J, Xie R, Zhu Z, Hong Z, et al. Epigenetic regulation of HBV-specific tumor-infiltrating T cells in HBV-related HCC. Hepatology. 2023;78:943\u201358.","journal-title":"Hepatology"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03625-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03625-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03625-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T23:03:00Z","timestamp":1763938980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03625-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":55,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2025,12,15]]}},"alternative-id":["3625"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03625-4","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All cancer patient samples were collected with the patients\u2019 written informed consent and approval from the Ethics Committee of Shenzhen People\u2019s Hospital (AUP-240730-CWB-411-01). Animal experiments were approved by the Animal Care Ethics Committee of Shenzhen People\u2019s Hospital. All animal experiments had complied with the ARRIVE guidelines and the National Institutes of Health guide for the care and use of Laboratory animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}